Kimberly J. Johnson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Kimberly J. Johnson has a total of 204 co-authors. Here are the top co-authors by number of shared publications:
- Justin Michael Barnes
Department of Radiation Oncology, Mayo Clinic, Rochester, MN
11 shared publications - David H. Gutmann
Department of Neurology, Washington University School of Medicine, St. Louis, USA
8 shared publications - Michael E. Scheurer
Emory University School of Medicine, Atlanta, Georgia, United States
5 shared publications Xiaoyan Wang
Brown School, Washington University in St. Louis, St. Louis, MO, USA
5 shared publications- Xiaoyan Wang
Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore
5 shared publications - Adelheid Woehrer
Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria
4 shared publications
Latest Publications
- Open Access
- 24 September 2026
- Published by Springer Nature in Cancer Causes & Control
- Vol. 37 (10) , 167
Prevalence and trends in recent alcohol consumption by cancer history and cancer type in a nationally representative sample of U.S. adults
Purpose: Alcohol consumption increases the risk of several cancer types. Using nationally representative data, we aimed to 1) quantify trends in alcohol consumption by cancer history and 2) estimate prevalence differences in alcohol consumption comparing individuals with vs. without a cancer history overall and by cancer type. Methods: We used Behavioral Risk Factor Surveillance System (BRFSS) cross-sectional data from 2016–2024 for trend and 2022–2024 for prevalence difference analyses. We calculated weighted prevalences of current (past-30-day alcohol consumption), binge, and heavy drinking among individuals with and without a cancer history. Annual percentage-point changes (APPCs) and adjusted prevalence differences were estimated using linear regression. Results: Data from 3,968,799 and 465,870 respondents were included in trend and prevalence difference analyses. Across all years, the current drinking prevalence was lower among individuals with a cancer history than without. Current drinking declined among those without a cancer history (53.9% in 2016 to 51.5% in 2024; APPC = − 0.28%, p <.05) but not among those with a cancer history (45.8% in both 2016 and 2024; APPC = 0.06%, p =.70). The adjusted prevalence of current and binge drinking was lower in those with a cancer history. By cancer type, the adjusted prevalence of current drinking was lower for most sites except for testicular, skin, and melanoma. Conclusions: Alcohol consumption was generally less prevalent among those with vs. without a reported cancer history and modestly declined over time in the latter group. These results inform the understanding of recent patterns in alcohol consumption by cancer history.
- 24 September 2026
- Published by Springer Nature in Cancer Causes & Control
- Vol. 37 (10) , 167
Open AccessPrevalence and trends in recent alcohol consumption by cancer history and cancer type in a nationally representative sample of U.S. adults
Purpose: Alcohol consumption increases the risk of several cancer types. Using nationally representative data, we aimed to 1) quantify trends in alcohol consumption by cancer history and 2) estimate prevalence differences in alcohol consumption comparing individuals with vs. without a cancer history overall and by cancer type. Methods: We used Behavioral Risk Factor Surveillance System (BRFSS) cross-sectional data from 2016–2024 for trend and 2022–2024 for prevalence difference analyses. We calculated weighted prevalences of current (past-30-day alcohol consumption), binge, and heavy drinking among individuals with and without a cancer history. Annual percentage-point changes (APPCs) and adjusted prevalence differences were estimated using linear regression. Results: Data from 3,968,799 and 465,870 respondents were included in trend and prevalence difference analyses. Across all years, the current drinking prevalence was lower among individuals with a cancer history than without. Current drinking declined among those without a cancer history (53.9% in 2016 to 51.5% in 2024; APPC = − 0.28%, p <.05) but not among those with a cancer history (45.8% in both 2016 and 2024; APPC = 0.06%, p =.70). The adjusted prevalence of current and binge drinking was lower in those with a cancer history. By cancer type, the adjusted prevalence of current drinking was lower for most sites except for testicular, skin, and melanoma. Conclusions: Alcohol consumption was generally less prevalent among those with vs. without a reported cancer history and modestly declined over time in the latter group. These results inform the understanding of recent patterns in alcohol consumption by cancer history.
- 10 June 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2600261
Paid Sick Leave, Care Delays, and Mortality Risk in Working Cancer Survivors
PURPOSE: Cancer survivors endure costly and time-intensive care throughout treatment and survivorship. Paid sick leave provides employment and financial stability while supporting time off for medical needs. We investigated whether paid sick leave is associated with financial hardship and overall and cancer-specific mortality risk in working adult cancer survivors. METHODS: Working adults age 18-64 years with a cancer history were identified from the National Health Interview Survey (NHIS) between 2011 and 2023. Associations of paid sick leave and financial hardship (medical care delays, problems paying medical bills, worry about paying medical bills, and cost-related medication underuse) were examined with 2011-2018 and 2019-2023 data using separate multivariable logistic regressions because of survey redesign in 2019. Linked mortality files from the National Death Index were available for 2011-2018 respondents. The association of paid sick leave and mortality risk was examined with multivariable Cox proportional hazards models. RESULTS: A total of 8,091 and 3,919 working cancer survivors were identified from the 2011-2018 and 2019-2023 NHIS, respectively. Paid sick leave was associated with decreased medical care delays because of cost (2011-2018 odds ratio [OR], 0.74 [95% CI, 0.60 to 0.93]; P = .008; 2019-2023 OR, 0.51 [95% CI, 0.35 to 0.74]; P < .001) but not consistently with other forms of financial hardship. In adjusted analyses, paid sick leave was associated with significant reductions in risk of overall mortality (hazard ratio [HR], 0.74 [95% CI, 0.61 to 0.9]; P = .003) and cancer mortality (HR, 0.74 [95% CI, 0.61 to 0.91]; P = .003). CONCLUSION: In working cancer survivors, paid sick leave is associated with decreased care delays and lower overall and cancer-specific mortality risk, which may be due to maintained employment, household income, and health insurance coverage leading to improvements in treatment access, affordability, and overall survivorship care.
- 10 June 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2600261
Paid Sick Leave, Care Delays, and Mortality Risk in Working Cancer Survivors
PURPOSE: Cancer survivors endure costly and time-intensive care throughout treatment and survivorship. Paid sick leave provides employment and financial stability while supporting time off for medical needs. We investigated whether paid sick leave is associated with financial hardship and overall and cancer-specific mortality risk in working adult cancer survivors. METHODS: Working adults age 18-64 years with a cancer history were identified from the National Health Interview Survey (NHIS) between 2011 and 2023. Associations of paid sick leave and financial hardship (medical care delays, problems paying medical bills, worry about paying medical bills, and cost-related medication underuse) were examined with 2011-2018 and 2019-2023 data using separate multivariable logistic regressions because of survey redesign in 2019. Linked mortality files from the National Death Index were available for 2011-2018 respondents. The association of paid sick leave and mortality risk was examined with multivariable Cox proportional hazards models. RESULTS: A total of 8,091 and 3,919 working cancer survivors were identified from the 2011-2018 and 2019-2023 NHIS, respectively. Paid sick leave was associated with decreased medical care delays because of cost (2011-2018 odds ratio [OR], 0.74 [95% CI, 0.60 to 0.93]; P = .008; 2019-2023 OR, 0.51 [95% CI, 0.35 to 0.74]; P < .001) but not consistently with other forms of financial hardship. In adjusted analyses, paid sick leave was associated with significant reductions in risk of overall mortality (hazard ratio [HR], 0.74 [95% CI, 0.61 to 0.9]; P = .003) and cancer mortality (HR, 0.74 [95% CI, 0.61 to 0.91]; P = .003). CONCLUSION: In working cancer survivors, paid sick leave is associated with decreased care delays and lower overall and cancer-specific mortality risk, which may be due to maintained employment, household income, and health insurance coverage leading to improvements in treatment access, affordability, and overall survivorship care.
- 10 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2500596
Associations of State Mandatory Paid Sick Leave Policies With Cancer Outcomes in the United States
PURPOSE: Since 2012, several states have implemented mandatory paid sick leave (PSL) policies. PSL can provide patients time and income continuity to undergo screening and/or timely diagnostic workup for new cancer-related symptoms and complete lengthy and expensive cancer treatment courses. This study aimed to examine the association between mandatory PSL policies and cancer stage at diagnosis and overall survival (OS). METHODS: Adults age 18-64 years diagnosed with cancer were identified from the Surveillance, Epidemiology, and End Results program registries between 2010 and 2019. Difference-in-differences (DID) analyses were used to compare absolute changes in stage I and stage IV diagnoses and 1-year OS before and after policy implementation in states that enacted mandatory PSL relative to states that did not enact such policies. RESULTS: A total of 1,052,307 patients with cancer were included. In adjusted DID analyses, there were a 0.83 (95% CI = –1.49 to –0.16, P = .014) PP decrease in stage IV diagnoses and a 0.63 (95% CI = 0.10 to 1.17, P = .021) PP increase in 1-year OS associated with implementation of mandatory PSL policies. In exploratory analyses, males and individuals with lung cancer experienced the greatest shifts in policy-associated changes in stage at diagnosis and OS. CONCLUSION: PSL policy implementation is associated with decreased late-stage diagnoses and improved OS in patients with cancer. Policies that improve opportunities to receive medical care may facilitate earlier cancer detection and ultimately contribute to better patient outcomes.
- 10 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2500596
Associations of State Mandatory Paid Sick Leave Policies With Cancer Outcomes in the United States
PURPOSE: Since 2012, several states have implemented mandatory paid sick leave (PSL) policies. PSL can provide patients time and income continuity to undergo screening and/or timely diagnostic workup for new cancer-related symptoms and complete lengthy and expensive cancer treatment courses. This study aimed to examine the association between mandatory PSL policies and cancer stage at diagnosis and overall survival (OS). METHODS: Adults age 18-64 years diagnosed with cancer were identified from the Surveillance, Epidemiology, and End Results program registries between 2010 and 2019. Difference-in-differences (DID) analyses were used to compare absolute changes in stage I and stage IV diagnoses and 1-year OS before and after policy implementation in states that enacted mandatory PSL relative to states that did not enact such policies. RESULTS: A total of 1,052,307 patients with cancer were included. In adjusted DID analyses, there were a 0.83 (95% CI = –1.49 to –0.16, P = .014) PP decrease in stage IV diagnoses and a 0.63 (95% CI = 0.10 to 1.17, P = .021) PP increase in 1-year OS associated with implementation of mandatory PSL policies. In exploratory analyses, males and individuals with lung cancer experienced the greatest shifts in policy-associated changes in stage at diagnosis and OS. CONCLUSION: PSL policy implementation is associated with decreased late-stage diagnoses and improved OS in patients with cancer. Policies that improve opportunities to receive medical care may facilitate earlier cancer detection and ultimately contribute to better patient outcomes.
- 10 February 2026
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 176 (3) , 205
SEER-Medicaid and SEER-Medicare data for neuro-oncology research
- 10 February 2026
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 176 (3) , 205
SEER-Medicaid and SEER-Medicare data for neuro-oncology research
- Open Access
- 15 January 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (6) , 723-734
Disparities in Allogeneic Hematopoietic Stem Cell Transplantation Among Acute Myeloid Leukemia Patients
- 15 January 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (6) , 723-734
Open AccessDisparities in Allogeneic Hematopoietic Stem Cell Transplantation Among Acute Myeloid Leukemia Patients
- Open Access
- 1 August 2025
- Published by MDPI AG in Zoonotic Diseases
- Vol. 5 (3) , 22
Evaluation of an Artificial Intelligence-Generated Health Communication Material on Bird Flu Precautions
The 2025 avian influenza A(H5N1) outbreak has highlighted the urgent need for rapidly generated health communication materials during public health emergencies. Artificial intelligence (AI) systems offer transformative potential to accelerate content development pipelines while maintaining scientific accuracy and impact. We evaluated an AI-generated health communication material on bird flu precautions among 100 U.S. adults. The material was developed using ChatGPT for text generation based on CDC guidelines and Leonardo.AI for illustrations. Participants rated perceived message effectiveness, quality, realism, relevance, attractiveness, and visual informativeness. The AI-generated health communication material received favorable ratings across all dimensions: perceived message effectiveness (3.83/5, 77%), perceived message quality (3.84/5, 77%), realism (3.72/5, 74%), relevance (3.68/5, 74%), attractiveness (3.62/5, 74%), and visual informativeness (3.35/5 67%). Linear regression analysis revealed that all features significantly predicted perceived message effectiveness in unadjusted and adjusted models (p < 0.0001), e.g., multivariate analysis of outcome on perceived visual informativeness showed β = 0.51, 95% CI: 0.37–0.66, p < 0.0001. Also, mediation analysis revealed that visual informativeness accounted for 23.8% of the relationship between material attractiveness and perceived effectiveness. AI tools can enable real-time adaptation of prevention guidance during epidemiological emergencies while maintaining effective risk communication.
- 1 August 2025
- Published by MDPI AG in Zoonotic Diseases
- Vol. 5 (3) , 22
Open AccessEvaluation of an Artificial Intelligence-Generated Health Communication Material on Bird Flu Precautions
The 2025 avian influenza A(H5N1) outbreak has highlighted the urgent need for rapidly generated health communication materials during public health emergencies. Artificial intelligence (AI) systems offer transformative potential to accelerate content development pipelines while maintaining scientific accuracy and impact. We evaluated an AI-generated health communication material on bird flu precautions among 100 U.S. adults. The material was developed using ChatGPT for text generation based on CDC guidelines and Leonardo.AI for illustrations. Participants rated perceived message effectiveness, quality, realism, relevance, attractiveness, and visual informativeness. The AI-generated health communication material received favorable ratings across all dimensions: perceived message effectiveness (3.83/5, 77%), perceived message quality (3.84/5, 77%), realism (3.72/5, 74%), relevance (3.68/5, 74%), attractiveness (3.62/5, 74%), and visual informativeness (3.35/5 67%). Linear regression analysis revealed that all features significantly predicted perceived message effectiveness in unadjusted and adjusted models (p < 0.0001), e.g., multivariate analysis of outcome on perceived visual informativeness showed β = 0.51, 95% CI: 0.37–0.66, p < 0.0001. Also, mediation analysis revealed that visual informativeness accounted for 23.8% of the relationship between material attractiveness and perceived effectiveness. AI tools can enable real-time adaptation of prevention guidance during epidemiological emergencies while maintaining effective risk communication.
- 3 October 2024
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 12 (2) , 246-256
Associations between central nervous system tumor diagnosis stage and survival and Medicaid enrollment among children, adolescents, and young adults
Background: Medicaid enrollment has been associated with disparities in younger cancer patient survival. To further understand this association for central nervous system (CNS) tumor patients, we used Surveillance, Epidemiology, and End Results (SEER)-Medicaid-linked data to examine associations between Medicaid enrollment and enrollment timing and (1) diagnosis stage, and (2) CNS tumor death. Methods: Individuals diagnosed with a first malignant primary CNS tumor between 0 and 39 years from 2006 to 2013 were included. Medicaid enrollment was first classified as enrolled versus not enrolled with those enrolled further classified as having continuous, discontinuous (at diagnosis or other discontinuous), or other enrollment. We used logistic and Cox Proportional Hazards regression stratified by age to calculate adjusted odds ratios (ORs) and hazard ratios (HRs) for those 0–14 and 15–39 years. Results: Among 10 107 CNS tumor patients, we found significantly higher odds of regional/distant versus in situ/localized stage diagnoses for those with other discontinuous (OR0–14 = 1.50, 95% CI: 1.15–1.95) and at diagnosis (OR15–39 = 1.41, 95% CI: 1.11–1.78) Medicaid enrollment versus those not enrolled. Those enrolled versus not enrolled in Medicaid had a higher hazard of CNS tumor death for both age groups (HR0–14 = 1.60 95% CI: 1.37–1.86; HR15–39 = 1.50, 95% CI: 1.39–1.62) with the highest hazards for those enrolled at diagnosis (HR0–14 = 1.83, 95% CI: 1.51–2.22; HR15–39 = 1.93, 95% CI: 1.77–2.10). Conclusions: Medicaid enrollment is associated with a higher risk of CNS tumor death with an almost 2-fold higher risk for young CNS tumor patients enrolled at diagnosis. These results support the critical need for consistent health insurance coverage for young CNS tumor patients.
- 3 October 2024
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 12 (2) , 246-256
Associations between central nervous system tumor diagnosis stage and survival and Medicaid enrollment among children, adolescents, and young adults
Background: Medicaid enrollment has been associated with disparities in younger cancer patient survival. To further understand this association for central nervous system (CNS) tumor patients, we used Surveillance, Epidemiology, and End Results (SEER)-Medicaid-linked data to examine associations between Medicaid enrollment and enrollment timing and (1) diagnosis stage, and (2) CNS tumor death. Methods: Individuals diagnosed with a first malignant primary CNS tumor between 0 and 39 years from 2006 to 2013 were included. Medicaid enrollment was first classified as enrolled versus not enrolled with those enrolled further classified as having continuous, discontinuous (at diagnosis or other discontinuous), or other enrollment. We used logistic and Cox Proportional Hazards regression stratified by age to calculate adjusted odds ratios (ORs) and hazard ratios (HRs) for those 0–14 and 15–39 years. Results: Among 10 107 CNS tumor patients, we found significantly higher odds of regional/distant versus in situ/localized stage diagnoses for those with other discontinuous (OR0–14 = 1.50, 95% CI: 1.15–1.95) and at diagnosis (OR15–39 = 1.41, 95% CI: 1.11–1.78) Medicaid enrollment versus those not enrolled. Those enrolled versus not enrolled in Medicaid had a higher hazard of CNS tumor death for both age groups (HR0–14 = 1.60 95% CI: 1.37–1.86; HR15–39 = 1.50, 95% CI: 1.39–1.62) with the highest hazards for those enrolled at diagnosis (HR0–14 = 1.83, 95% CI: 1.51–2.22; HR15–39 = 1.93, 95% CI: 1.77–2.10). Conclusions: Medicaid enrollment is associated with a higher risk of CNS tumor death with an almost 2-fold higher risk for young CNS tumor patients enrolled at diagnosis. These results support the critical need for consistent health insurance coverage for young CNS tumor patients.
- Open Access
- 22 July 2024
- Published by Wolters Kluwer Health in Journal of Public Health Management & Practice
- Vol. 30 (5) , E211-E214
Repeated Exposure to COVID-19 Misinformation: A Longitudinal Analysis of Prevalence and Predictors in a Community Sample
Belief in health misinformation can affect individual health decisions and actions. Repeated exposure to the same misinformation strengthens its impact, yet little is known about how commonly repeated exposure occurs. To estimate the prevalence, we tracked exposure to 5 inaccurate COVID-19 claims every week for up to 23 consecutive weeks in a racially diverse panel of adults (n = 213). Repeated exposure was common: across the 5 claims, 10%-43% of respondents reported hearing the misinformation in ≥ 3 different weeks. Frontline workers were more likely than other community members to experience repeated exposure, with adjusted incidence rate ratios (IRRs) ranging from 1.8 to 4.9 across the 4 items. Repeated exposure was most common among older adults. Adjusted IRR for those ages ≥ 50 versus 18-29 years ranged from 1.8 to 2.5 per misinformation claim. Public health planning efforts to counter health misinformation should anticipate multiple exposures to the same false claim, especially in certain subgroups.
- 22 July 2024
- Published by Wolters Kluwer Health in Journal of Public Health Management & Practice
- Vol. 30 (5) , E211-E214
Open AccessRepeated Exposure to COVID-19 Misinformation: A Longitudinal Analysis of Prevalence and Predictors in a Community Sample
Belief in health misinformation can affect individual health decisions and actions. Repeated exposure to the same misinformation strengthens its impact, yet little is known about how commonly repeated exposure occurs. To estimate the prevalence, we tracked exposure to 5 inaccurate COVID-19 claims every week for up to 23 consecutive weeks in a racially diverse panel of adults (n = 213). Repeated exposure was common: across the 5 claims, 10%-43% of respondents reported hearing the misinformation in ≥ 3 different weeks. Frontline workers were more likely than other community members to experience repeated exposure, with adjusted incidence rate ratios (IRRs) ranging from 1.8 to 4.9 across the 4 items. Repeated exposure was most common among older adults. Adjusted IRR for those ages ≥ 50 versus 18-29 years ranged from 1.8 to 2.5 per misinformation claim. Public health planning efforts to counter health misinformation should anticipate multiple exposures to the same false claim, especially in certain subgroups.
- Open Access
- 20 May 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (5) , e0303280
Impact of COVID-19 pandemic on breast cancer screening in a large midwestern United States academic medical center
Background: Access to breast screening mammogram services decreased during the COVID-19 pandemic. Our objectives were to estimate: 1) the COVID-19 affected period, 2) the proportion of pandemic-associated missed or delayed screening encounters, and 3) pandemic-associated patient attrition in screening encounters overall and by sociodemographic subgroup. Methods: We included screening mammogram encounter EPIC data from 1-1-2019 to 12-31-2022 for females ≥40 years old. We used Bayesian State Space models to describe weekly screening mammogram counts, modeling an interruption that phased in and out between 3-1-2020 and 9-1-2020. We used the posterior predictive distribution to model differences between a predicted, uninterrupted process and the observed screening mammogram counts. We estimated associations between race/ethnicity and age group and return screening mammogram encounters during the pandemic among those with 2019 encounters using logistic regression. Results: Our analysis modeling weekly screening mammogram counts included 231,385 encounters (n = 127,621 women). Model-estimated screening mammograms dropped by >98% between 03-15-2020 and 05-24-2020 followed by a return to pre-pandemic levels or higher with similar results by race/ethnicity and age group. Among 79,257 women, non-Hispanic (NH) Asians, NH Blacks, and Hispanics had significantly (p < .05) lower odds of screening encounter returns during 2020–2022 vs. NH Whites with odds ratios (ORs) from 0.70 to 0.91. Among 79,983 women, those 60–69 had significantly higher odds of any return screening encounter during 2020–2022 (OR = 1.28), while those ≥80 and 40–49 had significantly lower odds (ORs 0.77, 0.45) than those 50–59 years old. A sensitivity analysis suggested a possible pre-existing pattern. Conclusions: These data suggest a short-term pandemic effect on screening mammograms of ~2 months with no evidence of disparities. However, we observed racial/ethnic disparities in screening mammogram returns during the pandemic that may be at least partially pre-existing. These results may inform future pandemic planning and continued efforts to eliminate mammogram screening disparities.
- 20 May 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (5) , e0303280
Open AccessImpact of COVID-19 pandemic on breast cancer screening in a large midwestern United States academic medical center
Background: Access to breast screening mammogram services decreased during the COVID-19 pandemic. Our objectives were to estimate: 1) the COVID-19 affected period, 2) the proportion of pandemic-associated missed or delayed screening encounters, and 3) pandemic-associated patient attrition in screening encounters overall and by sociodemographic subgroup. Methods: We included screening mammogram encounter EPIC data from 1-1-2019 to 12-31-2022 for females ≥40 years old. We used Bayesian State Space models to describe weekly screening mammogram counts, modeling an interruption that phased in and out between 3-1-2020 and 9-1-2020. We used the posterior predictive distribution to model differences between a predicted, uninterrupted process and the observed screening mammogram counts. We estimated associations between race/ethnicity and age group and return screening mammogram encounters during the pandemic among those with 2019 encounters using logistic regression. Results: Our analysis modeling weekly screening mammogram counts included 231,385 encounters (n = 127,621 women). Model-estimated screening mammograms dropped by >98% between 03-15-2020 and 05-24-2020 followed by a return to pre-pandemic levels or higher with similar results by race/ethnicity and age group. Among 79,257 women, non-Hispanic (NH) Asians, NH Blacks, and Hispanics had significantly (p < .05) lower odds of screening encounter returns during 2020–2022 vs. NH Whites with odds ratios (ORs) from 0.70 to 0.91. Among 79,983 women, those 60–69 had significantly higher odds of any return screening encounter during 2020–2022 (OR = 1.28), while those ≥80 and 40–49 had significantly lower odds (ORs 0.77, 0.45) than those 50–59 years old. A sensitivity analysis suggested a possible pre-existing pattern. Conclusions: These data suggest a short-term pandemic effect on screening mammograms of ~2 months with no evidence of disparities. However, we observed racial/ethnic disparities in screening mammogram returns during the pandemic that may be at least partially pre-existing. These results may inform future pandemic planning and continued efforts to eliminate mammogram screening disparities.
- 18 January 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (5) , e30861
Associations between Medicaid enrollment and diagnosis stage and survival among pediatric cancer patients
Background: Medicaid‐associated disparities in childhood and adolescent (pediatric) cancer diagnosis stage and survival have been reported. However, a key limitation of prior studies is the assessment of health insurance at a single time point. To evaluate Medicaid‐associated disparities more robustly, we used Surveillance, Epidemiology, and End Results (SEER)–Medicaid linked data to examine diagnosis stage and survival disparities in those (i) Medicaid‐enrolled and (ii) with discontinuous and continuous Medicaid enrollment.Methods: SEER–Medicaid linked data from 2006 to 2013 were obtained on cases diagnosed from 0 to 19 years. Medicaid enrollment was classified as enrolled versus not enrolled, with further classifications as continuous when enrolled 6 months before through 6 months after diagnosis, and discontinuous when not enrolled continuously for this period. We used multinomial logistic and Cox proportional hazards regression models to determine associations between enrollment measures, diagnosis stage, and cancer death adjusted for covariates.Results: Among 21,502 cases, a higher odds of distant stage diagnoses were observed in association with Medicaid enrollment (odds ratio [OR] = 1.56, 95% confidence interval [CI]: 1.48–1.65), with the highest odds for discontinuous enrollment (OR = 2.0, 95% CI: 1.86–2.15). Among 30,654 cases, any Medicaid enrollment, continuous enrollment, and discontinuous enrollment were associated with 1.68 (95% CI: 1.35–2.10), 1.66 (95% CI: 1.35–2.05), and 1.89 (95% CI: 1.54–2.33) times higher hazards of cancer death versus no enrollment, respectively.Conclusions: Medicaid enrollment, particularly discontinuous enrollment, is associated with a higher distant stage diagnosis odds and risk of death. This study supports the critical need for consistent health insurance coverage in children and adolescents.
- 18 January 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (5) , e30861
Associations between Medicaid enrollment and diagnosis stage and survival among pediatric cancer patients
Background: Medicaid‐associated disparities in childhood and adolescent (pediatric) cancer diagnosis stage and survival have been reported. However, a key limitation of prior studies is the assessment of health insurance at a single time point. To evaluate Medicaid‐associated disparities more robustly, we used Surveillance, Epidemiology, and End Results (SEER)–Medicaid linked data to examine diagnosis stage and survival disparities in those (i) Medicaid‐enrolled and (ii) with discontinuous and continuous Medicaid enrollment.Methods: SEER–Medicaid linked data from 2006 to 2013 were obtained on cases diagnosed from 0 to 19 years. Medicaid enrollment was classified as enrolled versus not enrolled, with further classifications as continuous when enrolled 6 months before through 6 months after diagnosis, and discontinuous when not enrolled continuously for this period. We used multinomial logistic and Cox proportional hazards regression models to determine associations between enrollment measures, diagnosis stage, and cancer death adjusted for covariates.Results: Among 21,502 cases, a higher odds of distant stage diagnoses were observed in association with Medicaid enrollment (odds ratio [OR] = 1.56, 95% confidence interval [CI]: 1.48–1.65), with the highest odds for discontinuous enrollment (OR = 2.0, 95% CI: 1.86–2.15). Among 30,654 cases, any Medicaid enrollment, continuous enrollment, and discontinuous enrollment were associated with 1.68 (95% CI: 1.35–2.10), 1.66 (95% CI: 1.35–2.05), and 1.89 (95% CI: 1.54–2.33) times higher hazards of cancer death versus no enrollment, respectively.Conclusions: Medicaid enrollment, particularly discontinuous enrollment, is associated with a higher distant stage diagnosis odds and risk of death. This study supports the critical need for consistent health insurance coverage in children and adolescents.